Drug prices and trends for brilinta

Subscribe to access the full database, or Subscribe
Drug Name	NDC	Price/Unit ($)	Unit	Date
BRILINTA 90 MG TABLET	00186-0777-39	7.21291	EACH	2024-12-18
BRILINTA 90 MG TABLET	00186-0777-60	7.21291	EACH	2024-12-18
BRILINTA 60 MG TABLET	00186-0776-60	7.21307	EACH	2024-12-18
>Drug Name	>NDC	>Price/Unit ($)	>Unit	>Date

Brilinta Market Analysis and Price Projections

Introduction to Brilinta

Brilinta, also known as ticagrelor, is an antiplatelet medication used primarily to prevent blood clots in patients with acute coronary syndrome (ACS), including those who have had a heart attack or are at risk of having one. It works by preventing platelets from clumping together to form clots that can cause heart attacks and strokes[2].

Market Size and Growth Projections

The global Brilinta market is anticipated to experience significant growth over the coming years. Here are some key projections:

The market size was valued at approximately $1,523.09 million in 2021 and is expected to grow at a Compound Annual Growth Rate (CAGR) of around 9-10.3% from 2021 to 2029, reaching nearly $3,034.87 million by 2029[2][4].
Another forecast suggests that the market could reach $3,692 million by 2031, growing at a CAGR of 9.2% during the forecast period (2023-2031)[3].

Key Market Drivers

Several factors are driving the growth of the Brilinta market:

Increasing Prevalence of ACS: The rising incidence of acute coronary syndrome and other cardiovascular diseases is a major driver. According to the World Health Organization (WHO), approximately 17 million people die each year due to cardiovascular disorders[2].
Rising Healthcare Expenditure: Increasing healthcare spending globally, particularly in regions like North America and Europe, is boosting the demand for effective treatment options like Brilinta[1][2].
Launch of Generic Versions: The approval and launch of generic versions of Brilinta are expected to increase market competition and accessibility, further driving growth[1][5].
Growing Demand for Effective Treatment Options: The need for robust preventive measures against cardiovascular diseases is driving the demand for Brilinta, given its efficacy in reducing the risk of recurrent cardiovascular events[2].

Market Restraints

Despite the positive outlook, there are several challenges that could restrain market growth:

High Cost: The high cost of Brilinta, with a supply of 60 tablets costing around $485, can be a significant barrier, especially for patients without adequate insurance coverage[5].
Alternative Treatment Options: The availability of other antiplatelet medications can reduce the market share of Brilinta[1].
Lack of Awareness: Limited awareness about Brilinta in developing regions can hamper its adoption and market growth[1].

Regional Analysis

The Brilinta market is segmented into several regions, each with its own growth dynamics:

North America: This region is expected to dominate the market due to the high prevalence of ACS and the availability of advanced healthcare infrastructure. The rising geriatric population and increasing per capita income are also significant factors[1][2][3].
Europe: Europe is the second-largest market, driven by the increasing adoption of Brilinta and the presence of advanced healthcare facilities[1][2].
Asia-Pacific: This region is anticipated to be the fastest-growing market, driven by the rising incidence of cardiovascular diseases, increasing per capita disposable incomes, and government initiatives to improve healthcare quality[1][2][3].
Middle East & Africa: This region is expected to witness steady growth, though it is limited by the lack of access to healthcare facilities[2].

Competitive Landscape

The Brilinta market is highly competitive, with several key players:

AstraZeneca: As the original developer of Brilinta, AstraZeneca holds a significant market share. Other major players include Pfizer Inc., Sanofi S.A., Eli Lilly and Company, and Bristol-Myers Squibb Company[1][2].
Generic Manufacturers: The entry of generic manufacturers is expected to intensify competition, providing more affordable options to patients[1][5].

Segmentation

The market is segmented based on several criteria:

Dosage Form: The 90 mg tablet segment dominates the market due to its high efficacy and recommendation in major ACS treatment guidelines[3][4].
Indication: The acute coronary syndrome segment is the largest, given the high prevalence of the condition and the effectiveness of Brilinta in treating it[1][2].
Distribution Channel: Hospital pharmacies are the primary distribution channel, reflecting the high demand for Brilinta in hospital settings[1].

Impact of COVID-19

The COVID-19 pandemic has had a significant impact on the Brilinta market:

Supply Chain Disruptions: The pandemic led to disruptions in supply chains and manufacturing operations, resulting in shortages of critical medications, including Brilinta[1].
Shift to Telemedicine: The pandemic accelerated the adoption of telemedicine and remote monitoring, creating new opportunities for the Brilinta market by improving patient access to healthcare services[1].

Key Benefits for Industry Participants and Stakeholders

Several factors are beneficial for industry participants and stakeholders:

Launch of Generic Versions: This is expected to increase market competition and make Brilinta more accessible to a wider patient population[1][5].
Increasing Focus on Patient-Centered Care: The growing emphasis on patient-centered care is driving the demand for effective treatment options like Brilinta[1].
Rising Demand for Personalized Medicine: The increasing demand for personalized medicine is driving innovation and growth in the Brilinta market[1].

Price Projections and Affordability

The cost of Brilinta remains a significant factor:

Current Pricing: A supply of 60 tablets of Brilinta 90 mg costs around $485, which is a substantial expense for many patients[5].
Generic Versions: The availability of generic versions is expected to reduce the cost and make the medication more affordable for a broader patient base[1][5].

Key Takeaways

The global Brilinta market is expected to grow significantly, driven by the increasing prevalence of ACS and the launch of generic versions.
North America and Europe are expected to dominate the market, with Asia-Pacific being the fastest-growing region.
The high cost of Brilinta and the availability of alternative treatments are key restraints.
The market is highly competitive, with AstraZeneca and other major pharmaceutical companies playing significant roles.
The COVID-19 pandemic has accelerated the adoption of telemedicine, which is beneficial for the market.

Frequently Asked Questions

1. What is the expected growth rate of the global Brilinta market?

The global Brilinta market is expected to grow at a CAGR of around 9-10.3% from 2021 to 2029[1][2].

2. Which region is expected to dominate the Brilinta market?

North America is expected to dominate the Brilinta market due to the high prevalence of ACS and advanced healthcare infrastructure[1][2][3].

3. What are the key factors driving the growth of the Brilinta market?

Key factors include the increasing prevalence of ACS, rising healthcare expenditure, and the launch of generic versions of Brilinta[1][2].

4. What are the main restraints to the growth of the Brilinta market?

The high cost of Brilinta, availability of alternative treatment options, and lack of awareness in developing regions are significant restraints[1][2].

5. How has the COVID-19 pandemic impacted the Brilinta market?

The pandemic has disrupted supply chains and manufacturing operations but has also accelerated the adoption of telemedicine and remote monitoring, improving patient access to Brilinta[1].

Cited Sources:

MarkWide Research - Brilinta Market 2024-2032 | Size, Share, Growth
Maximize Market Research - Brilinta Market - Global Industry Analysis and forecast (2022-2029)
Straits Research - Ticagrelor Market Size, Share, Analysis and Forecast to 2031
Cognitive Market Research - Brilinta Market Report 2024 (Global Edition)
Drugs.com - Brilinta Prices, Coupons, Copay Cards & Patient Assistance

Drug Price Trends for brilinta

Average Pharmacy Cost for brilinta

Brilinta Market Analysis and Financial Projection